07:00 , Jun 28, 2010 |  BC Week In Review  |  Clinical News

TOL101 regulatory update

FDA granted Orphan Drug designation for Tolera's TOL101 to treat Type I diabetes in patients ages 16 years or younger with preserved pancreatic beta-cell function. The mAb against alpha beta T cell receptor is...
08:00 , Jan 11, 2010 |  BioCentury  |  Emerging Company Profile

Tolera: Delta Force Improves Tolerance

Corporate Profile Tolera Therapeutics Inc. is developing a mAb against the alpha beta T cell receptor designed to improve upon the safety and tolerability of Genzyme Corp.'s Thymoglobulin, the market-leading antibody for induction therapy to prevent...
07:00 , Oct 14, 1996 |  BC Week In Review  |  Company News

The Scripps Research Institute other research news

The three-dimensional structure of the most common type of T cell receptor was published in Science. The orientation of the receptor as it binds the class I major histocompatibility complex (MHC) molecule also was determined....